Message #26 From:
NewsBot Date: September 21, 2006 06:00:00 AM
CLRI News Dutton Associates Announces Investment Opinion: Clearant Update: FDA Scrutiny of Tissue Recovery Practices Increases by Dutton Associates
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Sept. 21, 2006--Dutton Associates updates its coverage of Clearant Inc. (OTCBB:CLRI) discussing increasing scrutiny of tissue recovery practices, maintaining its rating at Speculative Buy and a $3.00 price target. The research note issued September 20, 2006 by Dutton senior analyst Sally H. Wallick, CFA is available at www.duttonassociates.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.
The FDA reminded tissue processors that they have to comply with FDA regulations, and donor eligibility requirements. The FDA comments come in the wake of two cases of serious violations in the past year that resulted in the recall of potentially contaminated tissue and of the FDA creation of a task force to determine if additional rules are needed to protect the public health. Also, the tissue industry's trade and accreditation group, the American Association of Tissue Banks, will begin inspecting tissue recovery organizations, including those that are unaccredited, that supply accredited tissue banks. We believe that Clearant's tissue sterilization technology, the Clearant Process(R), can play an important role in ensuring the safety of human tissue used for implants. We believe that the unique characteristics of Clearant's technology make it an effective sterilization option, and we are optimistic about a new direct distribution strategy initiated in the second quarter.
About Dutton Associates
Dutton Associates is one of the largest independent investment research firms in the U.S. Its 31 senior analysts are primarily CFAs and have expertise in many industries. Dutton Associates provides continuing analyst coverage of over 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.
The cost of enrollment in our one-year continuing research program is US $39,500 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $63,000 from the Company for 4 Research Reports with coverage commencing on 8/05/2005. We do not accept payment of our fees in company stock. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.
